These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 7715091

  • 21. Significance of trilineage myelodysplasia in de novo acute myeloid leukaemia during remission rather than at diagnosis.
    Tamura S, Takemoto Y, Wada H, Itoh T, Mori A, Saheki K, Okada M, Takatsuka H, Fujimori Y, Okamoto T, Kakishita E.
    Br J Haematol; 1998 Jun; 101(4):743-8. PubMed ID: 9674749
    [Abstract] [Full Text] [Related]

  • 22. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V, Tzouvara E, Vartholomatos G, Chaidos A, Tsiara S, Bourantas KL.
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [Abstract] [Full Text] [Related]

  • 23. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F, Granena A, Gahrton G, De Witte T, Gratwohl A, Reiffers J, Gorin NC.
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [Abstract] [Full Text] [Related]

  • 24. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 25. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P, Vítek A, Michalová K, Zemanová Z, Lukásová M.
    Vnitr Lek; 2003 Mar 15; 49(3):174-80. PubMed ID: 12728590
    [Abstract] [Full Text] [Related]

  • 26. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K.
    Bone Marrow Transplant; 2005 May 15; 35(10):965-70. PubMed ID: 15806131
    [Abstract] [Full Text] [Related]

  • 27. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.
    Biol Blood Marrow Transplant; 2005 Feb 15; 11(2):122-8. PubMed ID: 15682073
    [Abstract] [Full Text] [Related]

  • 28. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome.
    Russell JA, Larratt L, Brown C, Turner AR, Chaudhry A, Booth K, Woodman RC, Wolff J, Valentine K, Stewart D, Ruether JD, Ruether BA, Klassen J, Jones AR, Gyonyor E, Egeler M, Dunsmore J, Desai S, Coppes MJ, Bowen T, Anderson R, Poon MC.
    Bone Marrow Transplant; 1999 Dec 15; 24(11):1177-83. PubMed ID: 10642805
    [Abstract] [Full Text] [Related]

  • 29. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H.
    Cancer; 2005 Aug 01; 104(3):547-54. PubMed ID: 15973664
    [Abstract] [Full Text] [Related]

  • 30. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
    Shao B, Gao YR, Wang C, Yan SK, Cai Q, Jiang JL, Yang J, Bai HT, Zhao M, Zhao CX.
    Ai Zheng; 2006 Aug 01; 25(8):1007-12. PubMed ID: 16965684
    [Abstract] [Full Text] [Related]

  • 31. Acute myeloid leukemia in the elderly:--159 Nagoya case studies--Nagoya Cooperative Study Group for Elderly Leukemia.
    Nagura E, Minami S, Nagata K, Morishita Y, Takeyama H, Sao H, Suzuki H, Naoe T, Yokomaku S, Mizuno H, Murase T, Hirabayashi N, Takeo T, Tanimoto M, Kawashima K, Saito H.
    Nagoya J Med Sci; 1999 Nov 01; 62(3-4):135-44. PubMed ID: 10689875
    [Abstract] [Full Text] [Related]

  • 32. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.
    Yang DH, Lee JJ, Mun YC, Shin HJ, Kim YK, Cho SH, Chung IJ, Seong CM, Kim HJ.
    Am J Hematol; 2007 Jan 01; 82(1):1-5. PubMed ID: 16986129
    [Abstract] [Full Text] [Related]

  • 33. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
    Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, Skandali A, Sakellari I, Yataganas X, Hellenic Cooperative Group.
    Cancer; 2003 Apr 01; 97(7):1721-31. PubMed ID: 12655529
    [Abstract] [Full Text] [Related]

  • 34. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D.
    Am J Hematol; 2001 Aug 01; 67(4):227-33. PubMed ID: 11443634
    [Abstract] [Full Text] [Related]

  • 35. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov 01; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 36. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M.
    J Exp Clin Cancer Res; 2002 Dec 01; 21(4):481-7. PubMed ID: 12636093
    [Abstract] [Full Text] [Related]

  • 37. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.
    Cancer Res; 1998 Sep 15; 58(18):4173-9. PubMed ID: 9751631
    [Abstract] [Full Text] [Related]

  • 38. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
    Stasi R, Venditti A, Del Poeta G, Aronica G, Dentamaro T, Cecconi M, Stipa E, Scimò MT, Masi M, Amadori S.
    Cancer; 1996 Jun 15; 77(12):2476-88. PubMed ID: 8640696
    [Abstract] [Full Text] [Related]

  • 39. De-novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) and myelodysplastic remission marrow (AML/MRM).
    Tamura S, Kanamaru A.
    Leuk Lymphoma; 1995 Jan 15; 16(3-4):263-70. PubMed ID: 7719234
    [Abstract] [Full Text] [Related]

  • 40. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J, Shao ZH, Liu H, Bai J, Cao YR, He GS, Tu MF, Wang XL, Hao YS, Yang TY, Yang CL.
    Chin Med J (Engl); 2004 Jul 15; 117(7):963-7. PubMed ID: 15265365
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.